COGNITIVE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案旨在研究系统性红斑狼疮(SLE)受试者与匹配的正常健康对照组的认知功能随时间的变化。我们先前的工作表明，抗磷脂(APL)和抗核糖体P(抗P)抗体的持续存在与SLE的认知功能障碍有关。此外，西班牙裔(HA)种族似乎是认知功能障碍的一个单独的风险因素。这一发现与其他研究中在非裔美国人(AA)和HA SLE患者中观察到的更严重的病程总体上是一致的。本项目将检验的具体假设是：1.使用ANAM(自动神经心理评估指标)和ACR(美国风湿病学会)组件，与健康对照组相比，确定SLE患者认知功能定量测量随时间变化的幅度。2.确定SLE患者的认知障碍是否与持续阳性的生物标记物水平有关。 研究计划：我们将从狼疮诊所招募SLE患者参加研究。符合4个或4个以上ACR修订标准的系统性红斑狼疮患者将符合条件。女性和男性都将被录取。受试者不会因为他们目前有或有NPSLE(神经精神病学系统性红斑狼疮)表现而被排除在外。排除标准包括：既往服用ANAM的经验，头部创伤导致意识丧失的病史，目前非法药物或酒精滥用，已知的结构性脑损伤，无法完成研究后续研究，无法给予知情同意。 参与者将被要求确定一位愿意参与这项研究的朋友作为对照对象。每个SLE受试者将按年龄(5岁)、教育程度、性别和种族匹配一名健康对照受试者。此外，如果对照组的临床或实验室异常可能与SLE的诊断一致，则将被排除在外。这将通过实施结缔组织疾病筛查问卷来确定。 方法：每6个月进行一次神经学、认知学、精神病学、风湿学和免疫学系列评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is designed to study cognitive function over time in subjects with Systemic Lupus Erythematosus (SLE) versus a matched group of normal healthy controls. Our prior work demonstrates that the persistent presence of antiphospholipid (aPL) and anti-ribosomal P (anti-P) antibodies is associated with cognitive dysfunction in SLE. Also, Hispanic (HA) ethnicity appears to be a separate risk factor for cognitive dysfunction. This finding is consistent with the more severe disease course overall that has been observed in African American (AA) and HA SLE patients in other studies. The specific hypothesis which will be tested in this project are: 1. Determine the magnitude of change over time in the quantitative measures of cognitive function using ANAM (Automated Neuropsychological Assessment Metrics) and the ACR (American College of Rheumatology) battery among SLE patients compared with healthy controls. 2. Determine whether cognitive impairment in SLE patients is associated with persistently positive biomarker levels. RESEARCH PLAN: We will recruit SLE patients from the Lupus Clinic for enrollment in the study. SLE subjects meeting 4 or more ACR revised criteria for the classification of SLE will be eligible. Both women and men will be enrolled. Subjects will not be excluded because they currently have or have a history of NPSLE (Neuropsychiatric systemic lupus erythematosus) manifestations. Exclusion criteria include: prior experience taking ANAM, history of head trauma leading to loss of consciousness, current illicit drug or alcohol abuse, known structural brain lesion, inability to complete study follow-up, inability to give informed consent. Participants will be asked to identify a friend who is willing to participate in the study as a control subject. One healthy control subject will be matched to each SLE subject by age (¿5 years), education, gender, and ethnicity. In addition, controls will be excluded if they have clinical or laboratory abnormalities that could be consistent with the diagnosis of SLE. This will be determined by administering the Connective Tissue Disease Screening Questionnaire. METHODS: Serial neurological, cognitive, psychiatric, rheumatological, and immunological evaluations will be performed every 6 months.